Related Experiment Video
Updated: Jan 16, 2026
07:22
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
4.4K
Proteolysis-Targeting Chimera (PROTAC): Current Applications and Future Directions.
Gang Fan1,2, Shilin Chen3,2, Qingping Zhang4,2
1Medical Research Center Affiliated Nanshan Hospital of Shenzhen University Shenzhen China.
Medcomm
|October 6, 2025
Summary
Targeted protein degradation (TPD) revolutionizes drug discovery by actively removing disease proteins. Proteolysis-targeting chimeras (PROTACs) show significant clinical progress for challenging targets and complex diseases.
Area of Science:
- Drug Discovery and Development
- Molecular Biology
- Oncology
Background:
- Targeted protein degradation (TPD) offers a novel therapeutic strategy by actively eliminating disease-driving proteins, unlike traditional inhibition.
- This approach expands treatment options for previously undruggable targets, including transcription factors (MYC, STAT3) and mutant oncoproteins (KRAS G12C).
- Proteolysis-targeting chimeras (PROTACs) are the leading TPD platform, with clinical trials demonstrating significant progression.
Purpose of the Study:
- To comprehensively review PROTAC development across various therapeutic areas.
- To analyze key targets and evaluate the clinical progression of breakthrough PROTAC candidates.
- To discuss challenges and future directions in PROTAC technology for complex diseases.
Main Methods:
- Review of existing literature on PROTAC development and clinical trials.
- Analysis of PROTAC applications targeting kinases, hormone receptors, antiapoptotic proteins, and epigenetic modulators.
- Evaluation of clinical data for candidates like ARV-110, ARV-471, and BTK degraders.
Main Results:
- PROTACs are advancing clinically for targets like MYC, STAT3, KRAS G12C, and BTK.
- Successful clinical progression is noted for prostate cancer (ARV-110) and breast cancer (ARV-471) PROTACs.
- Key challenges such as the 'hook effect' and oral bioavailability limitations are identified.
Conclusions:
- PROTAC technology represents a paradigm shift in drug discovery, enabling the targeting of previously intractable proteins.
- Continued innovation in delivery strategies, tissue-specific design, and E3 ligase expansion is crucial for overcoming challenges.
- PROTACs hold significant potential for transforming the treatment of complex diseases resistant to conventional therapies.
Related Concept Videos
01:24Tagging and Fusion Proteins
8.3K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.3K
02:53Conservative Site-specific Recombination and Phase Variation
6.6K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.6K